blueprint-medicines

Blueprint inks deal to buy lung cancer biotech Lengo

Targeted cancer drug specialist Blueprint Medicines has agreed to pay $250 million upfront to acquire Lengo Therapeutics and its lead drug for lung cancer, a rival to already-approved therapies from Johnson & Johnson and Takeda. There’s another $215 million tied to the achievement of regulatory and sales-based milestones with LNG-451, a compound that targets tumours …

Blueprint inks deal to buy lung cancer biotech Lengo Read More »

Blueprint Medicines to buy cancer drug startup with potential edge over Takeda, J&J targeted therapies

Blueprint Medicines is paying $250 million up front to acquire Lengo Therapeutics, developer of targeted cancer therapies. The startup’s lead drug candidate is on track to begin human testing in non-small cell lung cancer, and Blueprint believes the small molecule has advantages over new targeted therapies from Johnson & Johnson and Takeda Pharmaceutical.

After Scotland says no, NICE backs Lilly’s Retsevmo for lung cancer

Eli Lilly’s RET inhibitor Retsevmo can now be prescribed on the NHS for people with RET fusion-positive advanced non-small cell lung cancer (NSCLC) in England and Wales, within the Cancer Drugs Fund (CDF). The recommendation from health technology assessment (HTA) agency NICE comes a couple of weeks after Retsevmo (selpercatinib) was cleared for use in …

After Scotland says no, NICE backs Lilly’s Retsevmo for lung cancer Read More »

Roche, Blueprint’s RET cancer drug Gavreto cleared in EU

Roche and Blueprint Medicines have opened a second front in their rivalry with Eli Lilly in RET-mutated cancers, after getting approval for Gavreto from the European Commission. Gavreto (pralsetinib) has been cleared as a first-line treatment of people with RET fusion-positive advanced non-small cell lung cancer (NSCLC), a disease that is diagnosed in around 37,000 …

Roche, Blueprint’s RET cancer drug Gavreto cleared in EU Read More »

PharmaShots Weekly Snapshots (November 08 – 12, 2021)

Eisai Presents Results of Lecanemab in P-IIb Study 201 Study for the Treatment of Alzheimer’s Disease at CTAD 2021 Published: Nov 12, 2021 | Tags: Eisai, Lecanemab, P-IIb, Study 201 Study, Alzheimer’s Disease, CTAD 2021 Novo Nordisk’s Wegovy (semaglutide) Receives CHMP’s Recommendation for Approval to Treat Obesity Published: Nov 12, 2021 | Tags: Novo Nordisk, …

PharmaShots Weekly Snapshots (November 08 – 12, 2021) Read More »

Blueprint Medicines Signs an Exclusive Collaboration and License Agreement with Zai Lab to Develop and Commercialize BLU-945 and BLU-701 in Greater China

Shots: Blueprint will receive $25M up front, ~$590M in milestones along with royalties on net sales of BLU-945 & BLU-701 in Greater China & will retain all rights to BLU-945 & BLU-701 globally Zai Lab will get the rights to develop & exclusively commercialize BLU-945 & BLU-701 in  Greater China & will lead the development …

Blueprint Medicines Signs an Exclusive Collaboration and License Agreement with Zai Lab to Develop and Commercialize BLU-945 and BLU-701 in Greater China Read More »

PharmaShots Weekly Snapshots (June 14 – 18, 2021)

Lineage Signs an Exclusive Option Agreement with Amasa Therapeutics to Supply and Use of Clinical-Grade Hystem Published: June 18, 2021 | Tags: Lineage, Option Agreement, Amasa Therapeutics, Clinical-Grade Hystem BioNTech Reports First Patient Dosing in P-II Clinical Trial of BNT111 to Treat Advanced Melanoma Published: June 18, 2021 | Tags: BioNTech, P-II, Clinical Trial, BNT111, …

PharmaShots Weekly Snapshots (June 14 – 18, 2021) Read More »

Blueprint’s latest approval for Ayvakit sets up clash with Novartis

Blueprint Medicines has claimed its second FDA approval for Ayvakit, getting the nod for advanced systemic mastocytosis (SM), a group of rare blood cancers currently treated mainly by Novartis’ Rydapt.  The FDA has cleared Ayvakit (avapritinib) for adults with SM, including the three major subtypes – aggressive disease with or without an associated haematological neoplasm, …

Blueprint’s latest approval for Ayvakit sets up clash with Novartis Read More »

Blueprint Medicines’ Ayvakit (avapritinib) Receives FDA’s Approval to Treat Patients with Advanced Systemic Mastocytosis

Shots: The full FDA approval is based on data from 2 clinical trials i.e., P-I EXPLORER & P-II PATHFINDER trial evaluating the efficacy of Ayvakit (200 mg, PO, qd) in 53 adults with advanced SM including ASM, SM-AHN & MCL Results: @median follow-up of 11.6 mos., ORR (57%), CR/CRh (28%), PR (28 %) & clinical …

Blueprint Medicines’ Ayvakit (avapritinib) Receives FDA’s Approval to Treat Patients with Advanced Systemic Mastocytosis Read More »

Roche, Blueprint raise pressure on Lilly with new Gavreto approval

The FDA has cleared Roche and Blueprint Medicine’s Gavreto for a new use in RET-mutated thyroid cancer, putting it on a level playing field with Eli Lilly’s rival therapy Retevmo. The US regulator says Gavreto (pralsetinib) can be used to treat patient aged over 12 with advanced or metastatic RET-mutant thyroid tumours, adding to its …

Roche, Blueprint raise pressure on Lilly with new Gavreto approval Read More »

European regulators back Blueprint’s Ayvakyt for stomach tumours

European regulators have recommended a licence for Blueprint Medicines’ Ayvakyt (avapritinib), for adults with stomach tumours with certain mutations. Blueprint specialises in drugs that tackle cancers on the basis of the mutations they harbour, and has already had the drug approved by the FDA at the beginning of the year. This positive opinion from the …

European regulators back Blueprint’s Ayvakyt for stomach tumours Read More »

Roche pays Blueprint $675M upfront for ex-U.S. development, commercialization rights to cancer drug

Under the deal, Blueprint will additionally be eligible for more than $900M in milestone payments plus royalties for the RET inhibitor pralsetinib. The deal includes exclusive rights for Roche in ex-U.S. markets other than China and shared rights in the U.S.